Endometriose und Malignom

review OA: closed CC0 ⤵ 13 in-corpus citations
AI-generated summary by claude@2026-06, 2026-06-08

Malignant tumors rarely arise from endometriosis, primarily affecting the ovary and extragonadal sites like the rectosigmoid, with treatment involving resection and potentially radiotherapy or progestin therapy.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

AI-generated deep summary by claude@2026-07, 2026-07-09 · read from full text

The paper reviews that malignant tumors arising from endometriosis are rare, reported at about 1%, with roughly 80% occurring in the ovary and 20% at extragonadal sites, most commonly the rectosigmoid and rectovaginal septum. It describes that extragonadal endometriosis-associated cancers are treated with complete resection followed by postoperative radiotherapy, sometimes with adjuvant progestin, and that endometriosis-associated ovarian carcinomas often present at lower stages and with lower grades, though poorer chemotherapy response is anticipated. It also notes explicit limitations of current understanding, including that estrogen monotherapy is considered a risk factor for these malignancies and that heterozygous loss and PTEN tumor suppressor mutations may be early events, but the overall evidence is derived from reported case frequencies and literature rather than a single prospective study. This paper is centrally about endometriosis — it focuses on endometriosis-associated malignancies, including ovarian and extragonadal transformation and related molecular factors like PTEN.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

Malignant tumors arising from endometriosis are rare. A frequency of about 1% has been reported with in 80% the ovary, and in 20% extragonadal sites being affected. The most common extragonadal manifestations are the rectosigmoid and the rectovaginal septum. For extragonadal malignant tumors arising from endometriosis, complete resection followed by post-operative radiotherapy, possibly plus adjuvant progestin therapy, is the treatment of choice. Endometriosis-associated ovarian carcinomas are likely to present with lower stage disease and predominantly lower grade tumors. While their treatment follows that of common ovarian cancer, a poorer response to chemotherapy must be considered. As unopposed estrogen replacement therapy has been identified as a risk factor for the development of endometriosis-associated cancer, it is not recommended for hormone replacement therapy in women with a history of endometriosis. Loss of heterozygosity and mutations of the PTEN tumor suppressor gene may be early events of tumorigenesis. Endometriosis and its malignant transformation, perhaps, may serve as a suitable model in this regard. According to recent studies, endometriosis is associated with an increased relative risk of non-Hodgkin lymphoma.
Full text 8,884 characters · extracted from oa-doi-fallback · click to expand
Subscribe to RSS DOI: 10.1055/s-2003-42277 © Georg Thieme Verlag Stuttgart · New York Endometriose und Malignom Endometriosis and MalignomaPublication History Publication Date: 23 September 2003 (online) Zusammenfassung Maligne Tumoren auf dem Boden einer Endometriose sind selten. Sie treten in etwa 1 % der Fälle auf, wovon 80 % auf das Ovar und 20 % auf extragonadale Manifestationen entfallen. Häufigste extragonadale Manifestationen sind das Rektosigmoid und das Septum rectovaginale. Die Therapie von extragonadalen Endometriose-assoziierten Karzinomen besteht in der Resektion möglichst im Gesunden mit postoperativer Radiatio, ggf. mit adjuvanter Gestagengabe. Endometriose- assoziierte Ovarialkarzinome präsentieren sich häufiger in früheren Stadien und häufiger mit G1-und G2-Differenzierung. Sie werden wie Ovarialkarzinome behandelt, wobei ein schlechteres Ansprechen auf eine Chemotherapie angenommen wird. Da eine Östrogenmonotherapie ein potenzieller Risikofaktor für das Auftreten von Endometriose-assoziierten Malignomen ist, wird sie bei positiver Anamnese für Endometriose als Hormonersatz in der Peri- und Postmenopause nicht empfohlen. Heterozygotieverlust und Mutationen des PTEN Tumorsuppressorgens könnten frühe Ereignisse der Malignisierung sein. Möglicherweise sind die Endometriose und ihre maligne Transformation ein geeignetes Modell zum Studium der Krebsentstehung. Endometriose ist nach aktuellen Studien mit einem etwas erhöhten relativen Risiko, an einem Non-Hodgkin-Lymphom zu erkranken, assoziiert. Abstract Malignant tumors arising from endometriosis are rare. A frequency of about 1 % has been reported with in 80 % the ovary, and in 20 % extragonadal sites being affected. The most common extragonadal manifestations are the rectosigmoid and the rectovaginal septum. For extragonadal malignant tumors arising from endometriosis, complete resection followed by post-operative radiotherapy, possibly plus adjuvant progestin therapy, is the treatment of choice. Endometriosis-associated ovarian carcinomas are likely to present with lower stage disease and predominantly lower grade tumors. While their treatment follows that of common ovarian cancer, a poorer response to chemotherapy must be considered. As unopposed estrogen replacement therapy has been identified as a risk factor for the development of endometriosis-associated cancer, it is not recommended for hormone replacement therapy in women with a history of endometriosis. Loss of heterozygosity and mutations of the PTEN tumor suppressor gene may be early events of tumorigenesis. Endometriosis and its malignant transformation, perhaps, may serve as a suitable model in this regard. According to recent studies, endometriosis is associated with an increased relative risk of non-Hodgkin lymphoma. Schlüsselwörter Endometriose - Kanzerisierung endometriose-assoziiert - Ovarialkarzinom - PTEN Tumorsuppressorgen - Non-Hodgkin-Lymphom Key words Endometriosis - tumorigenesis - ovarian cancer - PTEN tumor supressor gene - non-Hodgkin lymphoma Literatur - 1 Addison W A, Hammond C B, Parker R T. The occurence of adenocarcinoma in endometriosis of the rectovaginal septum during progestational therapy. Gynecol Oncol. 1979; 8 193-197 - 2 Aslani M, Scully R E. Primary carcinomas of the broad ligament. Report of four cases and review of the literature. Cancer. 1989; 64 1540-1545 - 3 Berger A, Rouzier R, Carnot F, Braunberger E, Cugnenc P -H, Danel C. Primary adenocarcinoma of the rectovaginal septum: a case report and literature review. Eur J Obstet Gynecol Reprod Biol. 2001; 95 111-113 - 4 Bischoff F Z, Simpson J L. Heritability and molecular genetic studies of endometriosis. Hum Reprod Update. 2000; 6 37-44 - 5 Brinton L A, Gridley G, Persson I, Baron J, Bergqvist A. Cancer risk after a hospital discharge diagnosis of endometriosis. Am J Obstet Gynecol. 1997; 176 572-579 - 6 Brooks J J, Wheeler J E. Malignancy arising in extragonadal endometriosis. Cancer. 1977; 40 3065-3073 - 7 Brunson G L, Barclay D L, Sanders M, Aroaz C A. Malignant extraovarian endometriosis: two case reports and review of the literature. Gynecol Oncol. 1988; 30 123-130 - 8 Erzen M, Rakar S, Klancnik B, Syrjanen K, Klancar B. Endometriosis- associated ovarian carcinoma (EAOC): an entity distinct from other ovarian carcinomas as suggested by nested case-control study. Gynecol Oncol. 2001; 83 100-108 - 9 Goldberg M I, Belinson J L, Hutson E D, Nordqvist S R. Clear cell carcinoma arising in endometriosis of the rectovaginal septum. Obstet Gynecol. 1978; 51 (Suppl) 38-40 - 10 Han A C, Hovenden S, Rosenblum N G, Salazar H. Adenocarcinoma arising in extragonadal endometriosis: an immunohistological study. Cancer. 1998; 83 1163-1169 - 11 Haskel S, Chen S S, Spiegel G. Vaginal endometrioid adenocarcinoma arising in vaginal endometriosis: a case report and literature review. Gynecol Oncol. 1989; 34 232-236 - 12 Heaps J M, Nieberg R K, Berek J S. Malignant neoplasms arising in endometriosis. Obstet Gynecol. 1990; 75 1023-1028 - 13 Hitti I F, Glasberg S S, Lubicz S. Clear cell carcinoma arising in extraovarian endometriosis: report of three cases and review of the literature. Gynecol Oncol. 1990; 39 314-320 - 14 Jones K D, Owen E, Berresford A, Sutton C. Endometrial adenocarcinoma arising from endometriosis of the rectosigmoid colon. Gynecol Oncol. 2002; 86 220-222 - 15 Martini M, Ciccarone M, Garganese G, Maggiore C, Evangelista A, Rahimi S, Zannoni G, Vittori G, Larocca L M. Possible involvement of hMLH1, p16 (INK4a) and PTEN in the malignant transformation of endometriosis. Int J Cancer. 2002; 102 398-406 - 16 McCluggage W G, Bryson C, Lamki H, Boyle D D. Benign, borderline, and malignant endometrioid neoplasia arising in endometriosis in association with tamoxifen therapy. Int J Gynecol Pathol. 2000; 19 276-279 - 17 Modesitt S C, Tortolero- Luna G, Robinson J B, Gershenson D M, Wolf J K. Ovarian and extraovarian endometriosis-associated cancer. Obstet Gynecol. 2002; 100 788-795 - 18 Mostoufizadeh M GH, Scully R E. Malignant tumors arising in endometriosis. Clin Obstet Gynecol. 1980; 23 951-954 - 19 Nishida M, Watanabe K, Sato N, Ichikawa Y. Malignant transformation of ovarian endometriosis. Gynecol Obstet Invest. 2000; 50 (Suppl 1) 18-25 - 20 Obata K, Morland S J, Watson R H, Hitchcock A, Chenevix-Trench O, Thomas E J, Campbell I G. Frequent PTEN/MMAC mutations in endometrioid but not serous or mucinous epithelial ovarian tumors. Cancer Res. 1998; 58 2095-2097 - 21 Olson J E, Cerhan J R, Janney C A, Anderson K E, Vachon C M, Sellers T A. Postmenopausal cancer risk after self-reported endometriosis diagnosis in the Iowa Women's Health Study. Cancer. 2002; 94 1612-1618 - 22 Reimnitz C, Brand E, Nieberg R K, Hacker N F. Malignancy arising in endometriosis associated with unopposed estrogen replacement. Obstet Gynecol. 1988; 71 444-447 - 23 Sainz de la Cuesta R, Eichhorn J H, Rice L W, Fuller AF A F, Nikrui N, Goff B A. Histologic transformation of benign endometriosis to early epithelial ovarian cancer. Gynecol Oncol. 1996; 60 238-244 - 24 Sampson J A. Endometrial carcinoma of ovary rising in endometrial tissue in that organ. Arch Surg. 1925; 10 1-72 - 25 Sato N, Tsunoda H, Nishida M, Morishita Y, Takimoto Y, Kubo T, Noguchi M. Loss of heterozygosity on 10q23.3 and mutations of the tumor suppressor gene PTEN in benign endometrial cyst of the ovary: possible sequence progression from benign endometriosis cyst to endometrioid carcinoma and clear cell carcinoma of the ovary. Cancer Res. 2000; 60 7052-7056 - 26 Sillem M, Prifti S, Monga B, Buvari P, Shamia U, Runnebaum B. Soluble urokinase-type plasminogen activator receptor is over-expressed in uterine endometrium from women with endometriosis. Mol Hum Reprod. 1997; 3 1101-1105 - 27 Slavin R E, Krum R, Van Dinh T. Endometriosis- associated intestinal tumors: a clinical and pathological study of 6 cases with a review of the literature. Hum Pathol. 2000; 31 456-463 - 28 Stern R C, Dash R, Bentley R C, Snyder M J, Haney A F, Robboy S J. Malignancy in endometriosis: frequency and comparison of ovarian and extraovarian types. Int J Gynecol Pathol. 2001; 20 133-139 - 29 Swiersz L M. Role of endometriosis in cancer and tumor development. Ann NY Acad Sci. 2002; 955 281-292 - 30 Ulrich U, Sillem M, Keckstein J. Endometriose: medikamentöse und chirurgische Therapie. Med Welt. 2002; 53 23-28 - 31 Yantiss R K, Clement P B, Young R H. Neoplastic and pre-neoplastic changes in gastrointestinal endometriosis: a study of 17 cases. Am J Surg Pathol. 2000; 24 513-524 - 32 Young E F, Gamble C N. Primary adenocarcinoma of the rectovaginal septum arising in endometriosis. Report of a case. Cancer. 1969; 24 597-601 Priv.-Doz. Dr. med. Uwe Ulrich Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe Klinikum der Universität zu Köln Kerpener Straße 34 50931 Köln Email: [email protected]

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Condition tags

endometriosis

MeSH descriptors

Endometriosis Ovarian Neoplasms Endometriosis Female Humans Ovarian Neoplasms Ovarian Neoplasms Ovarian Neoplasms Rectal Neoplasms Rectal Neoplasms Rectal Neoplasms Vaginal Neoplasms Vaginal Neoplasms Vaginal Neoplasms

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

Cited by (13)

Source provenance

europepmc
last seen: 2026-07-31T06:09:14.520117+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:12:44.121522+00:00
License: CC0 · commercial use OK